| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 138 | 2021 |
| Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone RR McKay, H Ye, W Xie, R Lis, C Calagua, Z Zhang, QD Trinh, SL Chang, ... Journal of Clinical Oncology 37 (11), 923, 2019 | 103 | 2019 |
| Expression of PD-L1 in hormone-naïve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide C Calagua, J Russo, Y Sun, R Schaefer, R Lis, Z Zhang, K Mahoney, ... Clinical Cancer Research 23 (22), 6812-6822, 2017 | 90 | 2017 |
| Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations AG Sowalsky, H Ye, M Bhasin, EM Van Allen, M Loda, RT Lis, ... Cancer research 78 (16), 4716-4730, 2018 | 61 | 2018 |
| Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer JW Russo, C Gao, SS Bhasin, OS Voznesensky, C Calagua, S Arai, ... Cancer research 78 (22), 6354-6362, 2018 | 51 | 2018 |
| Taxane resistance in prostate cancer is mediated by decreased drug-target engagement A Gjyrezi, F Xie, O Voznesensky, P Khanna, C Calagua, Y Bai, J Kung, ... The Journal of clinical investigation 130 (6), 3287-3298, 2020 | 48 | 2020 |
| Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer RR McKay, W Xie, H Ye, FM Fennessy, Z Zhang, R Lis, C Calagua, ... The Journal of urology 206 (1), 80-87, 2021 | 47 | 2021 |
| A subset of localized prostate cancer displays an immunogenic phenotype associated with losses of key tumor suppressor genes C Calagua, M Ficial, CS Jansen, T Hirz, L Del Balzo, S Wilkinson, R Lake, ... Clinical Cancer Research 27 (17), 4836-4847, 2021 | 24 | 2021 |
| Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer JW Russo, X Liu, H Ye, C Calagua, S Chen, O Voznesensky, J Condulis, ... Cancer letters 438, 97-104, 2018 | 24 | 2018 |
| Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer XT Gao, J Liang, LY Wang, Z Zhang, P Yuan, J Wang, Y Gao, F Ma, ... Molecular Oncology 15 (7), 1901-1920, 2021 | 23 | 2021 |
| Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer F Ma, S Arai, K Wang, C Calagua, AR Yuan, L Poluben, Z Gu, JW Russo, ... Cancer research 82 (8), 1518-1533, 2022 | 18 | 2022 |
| Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis … D Jones, JJ Guan, C Calagua, DE Hansel, JI Epstein, H Ye Human pathology 94, 58-63, 2019 | 9 | 2019 |
| Prostate cancer susceptibility gene HIST1H1A is a modulator of androgen receptor signaling and epithelial to mesenchymal transition HYNPSC Kendra A. Williams, Minnkyong Lee, Jean M. Winter, Derek E. Gildea ... Oncotarget 9 (47), 28532-28546, 2018 | 9 | 2018 |
| Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci J Fontugne, PY Cai, H Alnajar, B Bhinder, K Park, H Ye, S Beg, V Sailer, ... JCI insight 7 (4), 2022 | 8 | 2022 |
| Metastatic castration-resistant prostate cancer remains dependent on oncogenic drivers found in primary tumors DJ Einstein, S Arai, C Calagua, F Xie, O Voznesensky, BJ Capaldo, ... JCO Precision Oncology 5, 1514-1522, 2021 | 8 | 2021 |
| Tumor PD-L1 Expression is Detected in a Significant Subset of High-Risk Localized and Metastatic Prostate Cancer but is Rare in Ductal Subtype K Shaw, C Calagua, J Russo, D Einstein, S Balk, H Ye LABORATORY INVESTIGATION 99, 2019 | 8 | 2019 |
| Targeting EZH2 increases therapeutic efficacy of check-point blockade in models of prostate cancer AV Sheahan, KL Morel, DL Burkhart, SC Baca, DP Labbé, K Roehle, ... BioRxiv, 730135, 2019 | 7 | 2019 |
| A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa). DJ Einstein, XX Wei, L Werner, H Ye, C Calagua, G Bubley, SP Balk Journal of Clinical Oncology 37 (7_suppl), TPS341-TPS341, 2019 | 1 | 2019 |
| Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer A Sheahan, K Morel, D Burkhart, S Baca, D Labbè, K Roehle, C Calagua, ... Molecular Cancer Therapeutics 18 (12_Supplement), B006-B006, 2019 | | 2019 |
| PD-L1 Expression in Chromophobe Renal Cell Carcinomas R Ta, Z Mahdi, C Calagua, H Ye, D Lin LABORATORY INVESTIGATION 99, 2019 | | 2019 |
